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In the ﬁ fty years since the ﬁ rst Pula congress a lot 
has changed in neuropsychopharmacology. Granted, 
the major groups of psychoactive drugs had already 
been discovered: neuroleptics, antidepressants, ben-
zodiazepine anxiolitics, psychostimulants... Neu-
rology was using the basic antiepileptics while, for 
example, the treatments for vascular and immuno-
logical diseases were more expectative. At the time 
of the ﬁ rst Pula congress in 1960 we had only just 
discovered that myasthenia gravis is an autoimmune 
disease. It is also the year when dopamine deﬁ ciency 
in the brain of Parkinsonian patients was discovered, a 
ﬁ nding which was to revolutionize understanding and 
treatment of this disease. Th e last ﬁ fty years have also 
seen a proliferation of approaches to therapy and the 
success of these medical ﬁ elds has grown considerably. 
During this time, more than twenty researchers have 
been awarded the Nobel Prize for research related to 
functioning of the nervous system and have or will 
have a signiﬁ cant inﬂ uence on the development of 
new drugs. Th e greatest breakthroughs still waiting 
for clinical implementation have been in the ﬁ eld of 
basic research. Discoveries of excitotoxicity medi-
ated by glutamate receptors as well as neurogenesis 
in adults are creating brand new hypotheses on the 
pathophysiology of diﬀ erent psychiatric and neuro-
logical diseases ranging from schizophrenia and drug 
abuse to ALS. However, speaking subjectively, there 
are two developments that had the deepest and stron-
gest impact on pharmacology. First was the discovery 
of endogenous opioids based on the inquiry into real 
function of diﬀ erent pharmacological receptors in our 
organism. Th is discovery has shown that the so-called 
pharmacological receptors did not evolve solely for the 
purpose of drug-deliverance but that they also have a 
physiological purpose in the functioning of an organ-
ism. Th e second important event was the discovery 
of methodology of reverse pharmacology – instead 
of a classic approach, nowadays receptors are more 
and more often synthesized from the human genome 
followed by search for their endogenous ligands and 
possibilities of their pharmacological manipulation. 
Th rough this, we now have orexines (hypocretins) 
as key neurotransmitters of wakefulness. By reverse 
pharmacology we have discovered such receptors as 
the new opioid receptor ORL1 and its endogenous 
ligand, nociceptin and ﬁ nally, after several decades 
of diﬀ erent assumptions, the prolactin-stimulating 
factor. What is especially intriguing and motivating 
is the fact that there are still hundreds of G-protein 
receptors, nuclear receptors and synaptic receptors 
waiting for researchers to discover their function and 
useful implementation through pharmacology.
Pharmacology in 60’
Nobel prizes in Pharmacology
Fundamental change in conepts: coexistence of-
neurotransmitors, the question what really pharma-
cological reseptors Endogenous opioids, endozapines, 
endocanabinoids
Fundamentaly new reserch strategy: „Reverse 
pharmacology. Orexins, Prolactin stumulating factor
• 2009 - Elizabeth H. Blackburn, Carol W. Greider, Jack W. 
Szostak
• 2008 - Harald zur Hausen, Françoise Barré-Sinoussi, Luc 
Montagnier
• 2007 - Mario R. Capecchi, Sir Martin J. Evans, Oliver Smi-
thies
• 2006 - Andrew Z. Fire, Craig C. Mello
• 2005 - Barry J. Marshall, J. Robin Warren
• 2004 - Richard Axel, Linda B. Buck
• 2003 - Paul C. Lauterbur, Sir Peter Mansﬁ eld
• 2002 - Sydney Brenner, H. Robert Horvitz, John E. Sulston
• 2001 - Leland H. Hartwell, Tim Hunt, Sir Paul Nurse
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• 2000 - Arvid Carlsson, Paul Greengard, Eric R. Kandel
• 1999 - Günter Blobel
• 1998 - Robert F. Furchgott, Louis J. Ignarro, Ferid Murad
• 1997 - Stanley B. Prusiner
• 1996 - Peter C. Doherty, Rolf M. Zinkernagel
• 1995 - Edward B. Lewis, Christiane Nüsslein-Volhard, Eric 
F. Wieschaus
• 1994 - Alfred G. Gilman, Martin Rodbell
• 1993 - Richard J. Roberts, Phillip A. Sharp
• 1992 - Edmond H. Fischer, Edwin G. Krebs
• 1991 - Erwin Neher, Bert Sakmann
• 1990 - Joseph E. Murray, E. Donnall Th omas
• 1989 - J. Michael Bishop, Harold E. Varmus
• 1988 - Sir James W. Black, Gertrude B. Elion, George H. 
Hitchings
• 1987 - Susumu Tonegawa
• 1986 - Stanley Cohen, Rita Levi-Montalcini
• 1985 - Michael S. Brown, Joseph L. Goldstein
• 1984 - Niels K. Jerne, Georges J.F. Köhler, César Milstein
• 1983 - Barbara McClintock
• 1982 - Sune K. Bergström, Bengt I. Samuelsson, John R. Vane
• 1981 - Roger W. Sperry, David H. Hubel, Torsten N. Wiesel
• 1980 - Baruj Benacerraf, Jean Dausset, George D. Snell
• 1979 - Allan M. Cormack, Godfrey N. Hounsﬁ eld
• 1978 - Werner Arber, Daniel Nathans, Hamilton O. Smith
• 1977 - Roger Guillemin, Andrew V. Schally, Rosalyn Yalow
• 1976 - Baruch S. Blumberg, D. Carleton Gajdusek
• 1975 - David Baltimore, Renato Dulbecco, Howard M. Temin
• 1974 - Albert Claude, Christian de Duve, George E. Palade
• 1973 - Karl von Frisch, Konrad Lorenz, Nikolaas Tinbergen
• 1972 - Gerald M. Edelman, Rodney R. Porter
• 1971 - Earl W. Sutherland, Jr.
• 1970 - Sir Bernard Katz, Ulf von Euler, Julius Axelrod
• 1969 - Max Delbrück, Alfred D. Hershey, Salvador E. Luria
• 1968 - Robert W. Holley, H. Gobind Khorana, Marshall W. 
Nirenberg
• 1967 - Ragnar Granit, Haldan K. Hartline, George Wald
• 1966 - Peyton Rous, Charles B. Huggins
• 1965 - François Jacob, André Lwoﬀ , Jacques Monod
• 1964 - Konrad Bloch, Feodor Lynen
• 1963 - Sir John Eccles, Alan L. Hodgkin, Andrew F. Huxley
• 1962 - Francis Crick, James Watson, Maurice Wilkins
• 1961 - Georg von Békésy
• 1960 - Sir Frank Macfarlane Burnet, Peter Medawar
